ArticleMolecular therapy. Oncology2025
Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with limited treatment options. Oncolytic virus (OV) therapy exploits replication-competent viruses, including vesicular stomatitis virus (VSV), to preferentially infect and kill malignant cells, while sparing non-malignant cells. We previously showed that human PDAC cell lines are highly heterogeneous in their permissiveness to VSV and other OVs. Although ruxolitinib and other JAK1/2 inhibitors can enhance VSV replication in resistant PDAC cell lines, they also increase the susceptibility of non-malignant cells to OVs. Here, we show that fostamatinib (R788), a spleen tyrosine kinase (SYK) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of chronic immune thrombocytopenia (ITP), specifically boosts VSV replication in PDAC cells without affecting non-malignant cells. Fostamatinib treatment suppressed both the secretion of interferons and inflammatory cytokines by VSV-infected PDAC cells and diminished their responsiveness to type I interferons. However, unlike ruxolitinib, fostamatinib promoted viral replication without severely impeding innate immune responses essential for adaptive anti-cancer immunity. Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.